| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1000 | |
| Phytochemical name or plant extracts | Wedelolactone | |
| PMID | 25934092 | |
| Literature evidence | In this study, however, a novel biological activity of nM dose of wedelolactone was demonstrated. | |
| IUPAC name | 1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one | |
| Phytochemicals’ class or type of plant extracts | Coumestan | |
| Source of phytochemicals or plant Extracts | Sphagneticola calendulacea | |
| Geographical availability | Andaman Is., Assam, Bangladesh, Borneo, Cambodia, China Southeast, India, Japan, Jawa, Korea, Laccadive Is., Laos, Malaya, Manchuria, Myanmar, Nansei-shoto, Philippines, Sri Lanka, Taiwan, Thailand, Vietnam | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Prostate cancer | |
| Target gene or protein | ERα, ERβ, SoX2, ABCG2 | |
| Gene or Protein evidence | Wedelolactone acts as agonist of estrogen receptors (ER) α and β as demonstrated by transactivation of estrogen response element (ERE) in cells transiently expressing either ERα or ERβ and by molecular docking of this coumestan into ligand binding pocket of both ERα and ERβ. Enhanced drug retention was achieved by downregulation of SOX2 and ABCG2, both of which contribute to drug resistance of the CSCs. | |
| Target pathways | Akt/mTOR signaling | |
| IC50 | NA | |
| Potency | We conclude that wedelolactone acts as phytoestrogen in breast cancer cells by stimulating ER genomic and non-genomic signalling pathways. | |
| Cell line/ mice model | NA | |
| Additional information | NA | |
| PubChem ID | 5281813 | |
| Additional PMIDs | 22733624 25421824 25934092 28353647 31749430 21315506 30587555 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:993278-1 | |
| Safety | NA |